

RESEARCH MONOGRAPH . COMPOUND PROFILE

Daridorexant

A benzimidazole-triazole dual orexin receptor antagonist developed at Actelion and Idorsia Pharmaceuticals for the treatment of insomnia disorder, distinguished from earlier DORAs by an optimized pharmacokinetic profile yielding full-night sleep promotion with minimal next-morning residual impairment.

DOCUMENT	KDC-MN-1628
ISSUED	2026-05-21
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	Dual orexin receptor antagonist (DORA) with balanced OX1R and OX2R competitive antagonism

ABSTRACT

Daridorexant (ACT-541468, marketed as Quviviq) is an orally administered, competitive dual orexin receptor antagonist (DORA) approved by the United States Food and Drug Administration in January 2022 and by the European Medicines Agency in April 2022 for the treatment of insomnia disorder in adults. The compound binds both the orexin type 1 receptor (OX1R) and orexin type 2 receptor (OX2R) at sub-nanomolar affinities (K_i 0.47 nM at OX1R, 0.93 nM at OX2R), producing competitive, reversible blockade of the wake-promoting orexin A and orexin B neuropeptides without direct engagement of GABAergic, histaminergic, monoaminergic, or opioid receptor systems. In a selectivity panel of more than 130 central and peripheral pharmacological targets, daridorexant demonstrated no significant off-target binding, a profile that distinguishes it from the benzodiazepines and the Z-drugs (zolpidem, zaleplon, eszopiclone) and that underpins a mechanism-based rationale for preservation of physiological sleep architecture, absence of rebound insomnia on discontinuation, and low liability for tolerance and physical dependence.

The compound was discovered at Actelion Pharmaceuticals Ltd in Allschwil, Switzerland, under the leadership of Jean-Paul and Martine Clozel, and was selected from a large series of benzimidazole-containing dual orexin receptor antagonists on the basis of an optimized pharmacokinetic profile: a terminal elimination half-life of approximately 8 hours, oral bioavailability of 62 percent, rapid absorption (time to peak plasma concentration 1 to 2 hours), and a plasma clearance rate designed

to provide full-night sleep coverage at a dose of 25 to 50 mg while minimizing next-morning residual sedation at efficacious doses. When Actelion was acquired by Johnson and Johnson in June 2017, the drug discovery operations (including daridorexant) were spun off into the newly created Idorsia Pharmaceuticals Ltd, which advanced the compound through Phase 2 and Phase 3 clinical development and secured regulatory approval.

Two pivotal Phase 3 randomized, double-blind, placebo-controlled trials (Study 1, N=930; Study 2, N=924) conducted at 156 sites in 18 countries demonstrated statistically significant improvements in the co-primary endpoints of wake time after sleep onset (WASO) and latency to persistent sleep (LPS) measured by polysomnography at months 1 and 3. The 50 mg dose additionally improved patient-reported daytime functioning as measured by the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ), making daridorexant the first insomnia pharmacotherapy to demonstrate improvement on both nighttime sleep parameters and a validated daytime functioning instrument in a registration program. Sleep architecture analysis demonstrated preservation of rapid eye movement (REM) and non-REM sleep stage distributions, with no alteration of electroencephalographic spectral bands in N2, N3, or REM stages and no disruption of sleep spindle activity.

Pharmacokinetics are dominated by hepatic CYP3A4-mediated metabolism, which accounts for approximately 89 percent of metabolic clearance. Protein binding is exceptionally high at 99.7 percent; volume of distribution at steady state is 31 liters; and systemic clearance is 5.0 liters per hour. Concomitant administration with strong CYP3A4 inhibitors (itraconazole, clarithromycin, ritonavir) is contraindicated owing to a greater

than 400 percent increase in daridorexant exposure; moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole) require dose reduction to 25 mg. The compound is classified as a Schedule IV controlled substance in the United States on the basis of human abuse potential data demonstrating dose-dependent drug-liking effects in recreational sedative drug users, consistent with the scheduling of the other approved DORAs suvorexant and lemborexant.

The safety profile in pivotal trials and in a 40-week extension study (total treatment duration up to 12 months) demonstrated favorable tolerability. The most common adverse events were nasopharyngitis, headache, somnolence, and fatigue, occurring at low incidence. Adverse events of special interest (sleep paralysis, hypnagogic and hypnopompic hallucinations, cataplexy-like symptoms, suicidal ideation) were rare. No evidence of withdrawal symptoms, rebound insomnia, or tolerance was observed on abrupt discontinuation after up to 12 months of treatment. This monograph reviews the chemistry, synthesis, and structural pharmacology of daridorexant; the dual-receptor antagonist mechanism in molecular and functional detail; the comprehensive human pharmacokinetic record; the preclinical pharmacology in rodent and canine models; the clinical evidence base from Phase 1 through Phase 3 and long-term extension; sourcing and quality verification considerations; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal analysis; and a comparative assessment of five alternative insomnia pharmacotherapies against daridorexant on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Daridorexant.

Marketed name: Quviviq (Idorsia Pharmaceuticals Ltd; United States, European Union member states, Switzerland, United Kingdom, Canada, Japan, Australia).

Development code: ACT-541468 (Actelion/Idorsia). The development code is the canonical identifier in the early pharmacology literature and in the nonclinical characterization publications [1].

Chemical Abstracts Service registry numbers: 1505484-82-1 (free base), 1792993-84-0 (hydrochloride salt). The free base is the synthetic and research-grade form; the hydrochloride salt is the formulated pharmaceutical material.

International Union of Pure and Applied Chemistry name: [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl][5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone. The compound is a benzimidazole-pyrrolidine amide bearing a triazolyl-methoxyphenyl carbonyl group.

1.2 Structural class and chemistry

Daridorexant belongs to the dual orexin receptor antagonist (DORA) structural class, a group of competitive orthosteric antagonists that block both OX1R and OX2R. The structural scaffold comprises three principal pharmacophoric elements: a 5-chloro-4-methyl-1H-benzimidazole heterocycle providing the core receptor-binding motif; an (S)-2-methylpyrrolidine ring conferring conformational rigidity and stereochemical specificity; and a 5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoyl amide group connecting the pyrrolidine nitrogen to the triazolyl-methoxyphenyl unit [2, 3].

Molecular formula: C₂₃H₂₃ClN₆O₂ (free base); C₂₃H₂₄Cl₂N₆O₂ (hydrochloride salt).

Molecular weight: 450.92 g/mol (free base); 487.38 g/mol (hydrochloride salt).

Exact mass: 450.1571 g/mol (free base, monoisotopic).

Physical properties: White to off-white crystalline powder. The hydrochloride salt is soluble in water at pharmaceutical concentrations, in dimethyl sulfoxide, and in methanol. The compound is stable under standard storage conditions (room temperature, dry). Melting point data for the hydrochloride salt have been reported in the patent literature.

Stereochemistry: Daridorexant contains a single stereocenter at the 2-position of the pyrrolidine ring and is supplied exclusively as the (S)-enantiomer. The stereochemical assignment was established during the medicinal chemistry optimization program at Actelion and is critical for receptor binding; the (R)-enantiomer shows substantially reduced affinity for the orexin receptors. Investigators acquiring research-grade daridorexant should confirm enantiomeric purity by chiral high-performance liquid chromatography.

1.3 Synthesis

The published synthesis of daridorexant proceeds through a convergent strategy involving the preparation of two key intermediates and their coupling via amide bond formation [3, 4]. The first intermediate is (S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidine, prepared by condensation of a suitably protected (S)-proline derivative with a 4-chloro-5-methyl-1,2-diaminobenzene followed by cyclodehydration to form the benzimidazole ring. The second intermediate is 5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid, prepared by regioselective N-2 alkylation of 1,2,3-triazole onto a 2-halo-5-methoxybenzoate followed by ester hydrolysis. The final coupling step employs peptide coupling reagents (HATU with diisopropylethylamine in dichloromethane) to form the amide bond between the pyrrolidine nitrogen and the benzoic acid carbonyl. The product is purified by chromatography and recrystallization, and the hydrochloride salt is prepared by treatment with hydrogen chloride in a suitable solvent. Published yields for the final coupling step are approximately 30 percent; industrial optimization has improved this substantially for manufacturing scale. The compound is characterized by nuclear magnetic resonance spectroscopy, mass spectrometry, and chiral high-performance liquid chromatography.

2. Abstract

Daridorexant (ACT-541468, Quviviq) is a potent, selective, competitive dual antagonist of the orexin type 1 receptor (OX1R) and orexin type 2 receptor (OX2R), the first DORA approved with demonstrated efficacy on both nighttime sleep parameters and daytime functioning in registration-quality trials [5, 6]. The compound blocks the wake-promoting activity of the orexin neuropeptides (orexin A and orexin B, also termed hypocretin-1 and hypocretin-2) without engaging the broader inhibitory neurotransmitter systems targeted by benzodiazepines, Z-drugs, and antihistamines, and thereby promotes sleep through a fundamentally different pharmacological mechanism than the positive allosteric modulation of GABA-A receptors that has dominated insomnia pharmacotherapy for decades.

The compound was discovered through a targeted medicinal chemistry program at Actelion Pharmaceuticals and optimized for pharmacokinetic properties appropriate to full-night sleep coverage with minimal next-morning residual activity [1, 2]. With a terminal half-life of approximately 8 hours, oral bioavailability of 62 percent, and time to peak plasma concentration of 1 to 2 hours, daridorexant achieves effective orexin receptor occupancy through the full sleep period at doses of 25 and 50 mg while allowing sufficient clearance to minimize residual sedation upon morning awakening.

Two pivotal Phase 3 trials (Study 1, NCT03545191, N=930; Study 2, NCT03575104, N=924) established the efficacy and safety of daridorexant in adults with insomnia disorder [5]. The co-primary endpoints of wake time after sleep onset (WASO) and latency to persistent sleep (LPS), measured by polysomnography, showed statistically significant improvement versus placebo at months 1 and 3 for the 50 mg and 25 mg doses. The 50 mg dose additionally demonstrated significant improvement in patient-reported daytime functioning on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). Adverse events leading to discontinuation were low (1 to 3 percent) across all treatment groups. A 40-week extension study confirmed the durability of efficacy and the absence of new safety signals through 12 months of continuous treatment [7].

Daridorexant received FDA approval on January 10, 2022, and EMA approval in April 2022. It is classified as a Schedule IV controlled substance in the United States. The compound is the third DORA approved in the United States, following suvorexant (2014) and lemborexant (2019), and is distinguished from these predecessors by its optimized pharmacokinetic profile and its demonstrated improvement of day-time functioning.

3. Discovery and Development History

3.1 Origin

Daridorexant was synthesized at Actelion Pharmaceuticals Ltd in Allschwil, Switzerland, as part of an extensive medicinal chemistry program to identify a dual orexin receptor antagonist with pharmacokinetic properties optimized for the treatment of insomnia [1, 2]. The program was conducted under the scientific leadership of Jean-Paul Clozel and Martine Clozel, founders of Actelion. The orexin receptor target was validated by the discovery of the orexin neuropeptide system by Sakurai et al. in 1998 [8] and by the genetic association between orexin deficiency and narcolepsy established by Chemelli et al. in 1999 [9], observations that firmly established the orexin system as a central regulator of the sleep-wake transition and a pharmacologically tractable target for insomnia.

The development code ACT-541468 was assigned to daridorexant during the Actelion screening campaign. The compound was selected from a large series of benzimidazole-containing antagonists on the basis of balanced OX1R and OX2R affinity, high selectivity against off-target receptors, favorable oral pharmacokinetics (rapid absorption, moderate half-life, high bioavailability), and a projected pharmacokinetic profile that would produce effective receptor occupancy across the full 8-hour sleep period while clearing sufficiently to avoid next-morning impairment at therapeutic doses [1]. The compound was patented in 2013 and first described in the scientific literature in 2017.

3.2 Spin-off to Idorsia and clinical development

In June 2017, Johnson and Johnson completed the acquisition of Actelion for its marketed pulmonary arterial hypertension franchise. In connection with this acquisition, Actelion spun off its drug discovery operations and early-stage clinical development assets (including daridorexant, then in Phase 2) into Idorsia Pharmaceuticals Ltd, a newly created Swiss biopharmaceutical company led by Jean-Paul Clozel as chief executive officer and Martine Clozel as chief scientific officer. Idorsia advanced daridorexant through Phase 2 dose-finding studies and into the Phase 3 pivotal registration program.

3.3 Phase 2 development

A Phase 2 multicenter, randomized, double-blind, placebo-controlled, dose-response study evaluated daridorexant at doses of 5 mg, 10 mg, 25 mg, and 50 mg versus placebo in patients with insomnia disorder [10]. The study demonstrated dose-dependent improvements in polysomnographic measures (WASO, LPS, total sleep time) and established the 25 mg and 50 mg dose levels as the candidates for Phase 3 development. The 50 mg dose produced the most robust improvement on both objective and subjective endpoints, supporting its selection as the higher registration dose.

3.4 Phase 3 registration and regulatory approval

Two pivotal Phase 3 trials were initiated in 2018. Positive top-line results were announced in April 2020 (Study 1) and July 2020 (Study 2). Idorsia submitted the New Drug Application (NDA) to the FDA on January 8, 2021. The FDA accepted the NDA for review and granted approval on January 10, 2022, for the treatment of insomnia disorder in adults at doses of 25 mg and 50 mg, administered once nightly within 30 minutes of planned bedtime. The European Medicines Agency approved daridorexant (Quviviq) in April 2022. Subsequent approvals followed in Switzerland, the United Kingdom, Canada, Japan, and Australia. The compound became commercially available in the United States in May 2022.

3.5 Controlled substance scheduling

The DEA placed daridorexant in Schedule IV of the Controlled Substances Act, effective April 7, 2022, on the basis of human abuse potential data and the precedent of the other approved DORAs [11]. The scheduling reflects the dose-dependent drug-liking effects observed in recreational sedative drug users at supratherapeutic doses (100 mg and 150 mg) and the established class precedent of suvorexant (Schedule IV, 2014) and lemborexant (Schedule IV, 2019).

4. Mechanism of Action

Daridorexant is a competitive, reversible, orthosteric antagonist of both the orexin type 1 receptor (OX1R) and the orexin type 2 receptor (OX2R). The compound blocks the binding and signaling of the endogenous wake-promoting neuropeptides orexin A (hypocretin-1, 33 amino acids) and orexin B (hypocretin-2, 28 amino acids) to their cognate G-protein-coupled receptors, thereby reducing wake drive during the intended sleep period.

4.1 The orexin system and sleep-wake regulation

The orexin neuropeptide system consists of two peptide ligands (orexin A and orexin B) produced exclusively by a cluster of approximately 10,000 to 20,000 neurons in the lateral hypothalamus and perifornical area, and two G-protein-coupled receptors (OX1R and OX2R) expressed widely across the central nervous system [8, 9]. Orexin A binds both OX1R and OX2R with approximately equal affinity, while orexin B shows approximately 10-fold selectivity for OX2R over OX1R. Both receptors couple primarily through Gq and Gi/o proteins to activate phospholipase C, increase intracellular calcium, and depolarize postsynaptic neurons.

The orexinergic projection system innervates multiple arousal-promoting nuclei, including the locus coeruleus (noradrenergic), the dorsal raphe (serotonergic), the tuberomammillary nucleus (histaminergic), the ventral tegmental area (dopaminergic), and the basal forebrain (cholinergic). The orexin neurons are active during wakefulness, particularly during active exploration and motivated behavior, and are silent during both REM and NREM sleep. Loss of orexin signaling (as in narcolepsy type 1, caused by autoimmune destruction of orexin-producing neurons) produces excessive daytime sleepiness, fragmented nighttime sleep, and cataplexy, confirming the essential role of the orexin system in maintaining consolidated wakefulness [9, 12].

4.2 Receptor binding and selectivity

Daridorexant binds OX1R with a K_i of 0.47 nM and OX2R with a K_i of 0.93 nM, demonstrating approximately balanced potency at both receptor subtypes [1, 2]. The compound acts as a competitive antagonist at the orthosteric binding site, with reversible binding kinetics. In functional calcium mobilization assays, daridorexant inhibits orexin A-stimulated and orexin B-stimulated intracellular calcium release with IC_{50} values in the low nanomolar range.

Selectivity was assessed against a panel of more than 130 central and peripheral pharmacological targets, including GABA-A receptor subtypes, benzodiazepine binding sites, histamine H1 and H3 receptors, dopamine D1 through D5 receptors, serotonin receptor subtypes, adrenergic receptors, muscarinic receptors, opioid receptors (μ , δ , κ), and ion channels (hERG, sodium, calcium). Daridorexant showed no significant binding or functional activity at any of these targets at concentrations up to 10 micromolar, confirming high selectivity for the orexin receptors [1]. This selectivity profile is the molecular basis for the favorable side-effect profile relative to GABA-A receptor modulators, which produce widespread inhibition of neuronal activity across multiple brain regions and are associated with amnesia, ataxia, tolerance, dependence, and withdrawal.

4.3 Mechanism-based pharmacology

The pharmacological consequence of dual orexin receptor antagonism is selective reduction of wake drive during the period of receptor occupancy. By blocking the orexin signal that stabilizes wakefulness, daridorexant permits the natural sleep-promoting systems (including the ventrolateral preoptic area, the median preoptic nucleus, and the homeostatic sleep pressure pathway mediated by adenosine) to predominate, producing sleep that is initiated and maintained through physiological mechanisms rather than through widespread neuronal inhibition [13].

This mechanism produces several distinctive pharmacological features. First, sleep architecture is preserved: daridorexant does not suppress REM sleep (as benzodiazepines and many antidepressants do) and does not alter the spectral composition of NREM sleep stages or sleep spindle activity [14]. Second, the compound does not produce rebound insomnia upon discontinuation, because it does not alter the receptor density or sensitivity of the systems it modulates. Third, tolerance does not develop with chronic administration, because the mechanism does not involve receptor desensitization or compensatory upregulation [7]. Fourth, the risk of

physical dependence and withdrawal is low, because the compound does not engage the reinforcing neurotransmitter pathways (GABAergic, opioidergic, dopaminergic) that underlie the dependence liability of other sedative-hypnotic classes.

The dual (OX1R plus OX2R) antagonism of daridorexant is pharmacologically distinct from selective OX2R antagonism (as exemplified by seltorexant, SORA-2). OX2R is considered the principal receptor mediating the sleep-wake transition, while OX1R contributes to arousal, reward, anxiety, and autonomic regulation. The dual antagonism may provide more complete suppression of the wake-promoting signal and may additionally contribute to anxiolytic-like effects observed in pre-clinical models [15].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Daridorexant is well absorbed from the gastrointestinal tract after oral administration. Absolute oral bioavailability is 62 percent. Time to peak plasma concentration (T_{max}) is 1 to 2 hours under fasted conditions. High-fat meals delay T_{max} by approximately 1.3 hours and increase C_{max} by approximately 18 percent; these changes are not considered clinically meaningful and the compound may be taken with or without food, although administration is recommended within 30 minutes of planned bedtime [16, 17].

5.2 Distribution

Daridorexant has a volume of distribution at steady state of 31 liters, indicating distribution primarily within the vascular and extracellular compartments with moderate tissue partitioning. Plasma protein binding is exceptionally high at 99.7 percent, predominantly to albumin and alpha-1-acid glycoprotein. The blood-to-plasma ratio is 0.64, indicating preferential partitioning into the plasma compartment. The compound crosses the blood-brain barrier; central nervous system penetration is demonstrated by the pharmacodynamic effects on sleep architecture and by preclinical brain-to-plasma ratio measurements in rodent and canine models [1].

5.3 Metabolism

Daridorexant undergoes extensive hepatic metabolism. The principal metabolic pathway is oxidative biotransformation catalyzed by cytochrome P450 3A4 (CYP3A4), which accounts for approximately 89 percent of the total metabolic clearance [16, 17]. Other CYP isoforms contribute individually to less than 3 percent of metabolic clearance and are not clinically relevant. The metabolites are pharmacologically inactive or have substantially reduced orexin receptor affinity compared to the parent compound.

The CYP3A4 dependence is the source of the most clinically important pharmacokinetic drug interaction: concomitant strong CYP3A4 inhibitors (itraconazole, clarithromycin, ritonavir, ketoconazole, posaconazole, cobicistat) increase daridorexant area under the curve (AUC) by more than 400 percent and are contraindicated. Moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole, verapamil, grapefruit juice) increase AUC by approximately 240 percent and require dose reduction to 25 mg [16, 17].

CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort, efavirenz) reduce daridorexant exposure substantially and are expected to compromise efficacy. Concomitant use with strong CYP3A4 inducers is not recommended.

5.4 Elimination

Systemic clearance is 5.0 liters per hour. The terminal elimination half-life is approximately 8 hours, a value that was specifically targeted during the medicinal chemistry optimization to provide full-night sleep coverage (approximately 8 hours) with sufficient clearance to minimize next-morning residual effects [1]. Pharmacokinetic parameters following multiple-dose administration are similar to those observed following single-dose administration, with no clinically relevant accumulation.

Excretion is predominantly fecal: 50 to 69 percent of the administered radioactive dose is recovered in feces, and 24 to 35 percent in urine. Only trace amounts of unchanged parent drug are excreted, confirming that elimination is predominantly metabolic.

5.5 Route of administration

The compound is administered exclusively by the oral route. The registered formulation is a film-coated tablet containing 25 mg or 50 mg of daridorexant (as the hydrochloride salt). Administration is once nightly, within 30 minutes of planned bedtime, with at least 7 hours of intended sleep time remaining before the planned time of awakening.

5.6 Special populations

Renal impairment: Pharmacokinetics are not affected by renal impairment (mild, moderate, or severe). No dose adjustment is required [18].

Hepatic impairment: In patients with mild hepatic impairment (Child-Pugh A), no dose adjustment is required. In patients with moderate hepatic impairment (Child-Pugh B), the recommended dose is 25 mg. The compound has not been studied in severe hepatic impairment (Child-Pugh C) and is not recommended in this population [16].

Elderly patients: Elderly patients (age 65 years and older) were included in the Phase 3 pivotal trials and in the long-term extension study. No dose adjustment is required based on age alone.

Pediatric patients: Daridorexant has not been studied in pediatric patients (under 18 years of age) and is not approved for pediatric use.

6. Preclinical Pharmacology

6.1 In vitro pharmacology

Daridorexant demonstrated potent antagonism of both OX1R and OX2R in heterologous expression systems, with K_i values of 0.47 nM (OX1R) and 0.93 nM (OX2R) determined by radioligand displacement assays [1]. In functional calcium mobilization assays using cells expressing human OX1R or OX2R, daridorexant inhibited orexin A-stimulated intracellular calcium release in a concentration-dependent manner with IC_{50} values consistent with its binding affinity. The competitive nature of the antagonism was confirmed by Schild analysis, which yielded pA_2 values consistent with the K_i determinations.

The selectivity panel (more than 130 pharmacological targets) confirmed no significant off-target activity at concentrations up to 10 micromolar. Targets of particular relevance for a sleep-promoting agent that showed no binding include GABA-A receptor subtypes, benzodiazepine binding sites, histamine H1 receptors, muscarinic M1 through M5 receptors, and the dopamine transporter [1].

6.2 In vivo sleep-wake pharmacology

In freely moving rats instrumented for electroencephalographic and electromyographic recording, daridorexant at oral doses of 10, 30, and 100 mg/kg produced dose-dependent increases in both REM and NREM sleep time, with concomitant decreases in total wake time [1]. At the 30 mg/kg dose, NREM sleep latency decreased from 61 minutes (vehicle) to 13 minutes. Total NREM sleep time increased by up to 55 minutes and REM sleep time by up to 17 minutes at the highest dose studied. Total wake time decreased by up to 66 minutes. Sleep architecture analysis in the rodent studies demonstrated preservation of normal sleep stage distributions and no evidence of sleep stage suppression or disorganization.

Comparable sleep-promoting effects were observed in dog and mouse models, confirming cross-species translatability of the pharmacodynamic effect [1]. Importantly, the ratio of effective dose to brain exposure in the rodent correlated with the projected human therapeutic dose range, supporting the pharmacokinetic optimization strategy that selected daridorexant from the broader chemical series.

6.3 Comparison with zolpidem in preclinical models

A direct comparison between daridorexant and zolpidem in the rat sleep-wake EEG model demonstrated that both compounds promoted sleep, but with qualitatively different effects on sleep architecture. Zolpidem suppressed REM sleep and altered NREM EEG spectral characteristics, while daridorexant increased both NREM and REM sleep without altering EEG spectral power in any sleep stage [1]. This preclinical observation translated to the clinical finding that daridorexant preserves physiological sleep architecture in human insomnia patients.

6.4 Abuse potential assessment

Preclinical abuse potential was assessed in rats using conditioned place preference, self-administration, and drug discrimination paradigms [19]. Daridorexant did not produce conditioned place preference at any dose tested (10 to 100 mg/kg), was not self-administered by rats trained to self-administer zolpidem or midazolam, and did not substitute for zolpidem or midazolam in the drug discrimination paradigm. These findings are consistent with the absence of GABAergic, opioidergic, or dopaminergic receptor engagement and support the low intrinsic abuse liability of the compound.

6.5 Anxiolytic-like effects

Daridorexant produced anxiolytic-like effects in rat models, including the elevated plus maze and the Vogel conflict test, at doses that produced sleep promotion [15]. The anxiolytic effect is consistent with the OX1R antagonist component of the dual mechanism, as OX1R signaling has been implicated in anxiety-related behavior and stress-induced arousal. The clinical relevance of this preclinical observation has not been formally tested in a dedicated anxiety clinical trial.

6.6 Tolerance, dependence, and withdrawal

Repeated administration of daridorexant at doses up to 300 mg/kg in rats for 28 days produced no evidence of tolerance (maintained sleep-promoting efficacy throughout), no evidence of physical dependence (no withdrawal signs upon abrupt discontinuation), and no evidence of rebound insomnia (sleep parameters

returned to baseline without overshoot) [1, 19]. These preclinical findings are consistent with the clinical observation of absent tolerance and withdrawal in the 12-month extension study.

7. Clinical Evidence Base

7.1 Phase 1 studies

Phase 1 single-ascending-dose and multiple-ascending-dose studies in healthy volunteers established the pharmacokinetic profile, dose proportionality, and preliminary tolerability of daridorexant at doses from 5 mg to 200 mg [16]. The pharmacokinetic parameters confirmed the targeted profile: rapid absorption (T_{max} 1 to 2 hours), terminal half-life of approximately 8 hours, oral bioavailability of 62 percent, and dose-proportional exposure across the clinical dose range. Pharmacodynamic effects (subjective sleepiness, next-morning alertness) confirmed the expected onset and duration of action.

A human abuse potential study in recreational sedative drug users compared daridorexant at 50 mg (therapeutic), 100 mg, and 150 mg (suprathreshold) against placebo, zolpidem 30 mg, and suvorexant 40 mg [11]. Daridorexant 50 mg produced drug-liking scores similar to placebo. Daridorexant 100 mg and 150 mg produced greater drug-liking than placebo in a dose-dependent manner, with maximum effect broadly similar to zolpidem 30 mg and suvorexant 40 mg at the highest suprathreshold dose. These data supported the Schedule IV classification.

Drug-drug interaction studies confirmed the CYP3A4-mediated interaction profile. A study with the moderate CYP3A4 inhibitor diltiazem demonstrated a 240 percent increase in daridorexant AUC [16]. A study with citalopram (a CYP2C19 and CYP2D6 substrate) demonstrated no clinically meaningful pharmacokinetic interaction, supporting the use of daridorexant in patients receiving SSRI therapy [20].

7.2 Phase 2 dose-response study

A multicenter, randomized, double-blind, placebo-controlled, dose-response Phase 2 study evaluated daridorexant at 5 mg, 10 mg, 25 mg, and 50 mg versus placebo for 30 days in patients with insomnia disorder [10]. The co-primary endpoints were WASO and LPS measured by polysomnography. The study demonstrated dose-dependent improvements in WASO and LPS, with statistically significant effects at the 25 mg and 50 mg doses. Total sleep time (TST) increased in a dose-dependent manner. Patient-reported outcomes (sleep quality, daytime alertness) showed trends fa-

voring the 25 mg and 50 mg doses. The 10 mg dose showed numerical improvement but did not consistently reach statistical significance. The 5 mg dose did not demonstrate meaningful efficacy.

7.3 Phase 3 pivotal trials

Two Phase 3 multicenter, randomized, double-blind, placebo-controlled trials were conducted at 156 sites in 18 countries (United States, European Union member states, Switzerland, Japan, Australia, and others) [5].

Study 1 (NCT03545191): 930 adults (age 18 years and older) with insomnia disorder were randomized 1:1:1 to daridorexant 50 mg, daridorexant 25 mg, or placebo, administered once nightly for 3 months. Co-primary endpoints were WASO and LPS measured by polysomnography at months 1 and 3.

Study 2 (NCT03575104): 924 adults with insomnia disorder were randomized 1:1:1 to daridorexant 25 mg, daridorexant 10 mg, or placebo, administered once nightly for 3 months.

Efficacy results: In Study 1, daridorexant 50 mg produced statistically significant improvements in WASO at month 1 (least squares mean difference from placebo: approximately -22.8 minutes) and month 3 (approximately -18.3 minutes), and in LPS at month 1 (approximately -11.4 minutes) and month 3 (approximately -11.7 minutes). Daridorexant 25 mg produced significant improvements in WASO at both timepoints and in LPS at month 1. In Study 2, daridorexant 25 mg produced significant improvements in WASO at months 1 and 3 and in LPS at month 1. The 10 mg dose did not consistently achieve significance on the co-primary endpoints [5].

Daytime functioning: Daridorexant 50 mg produced statistically significant improvement on the IDSIQ total score at month 1 and month 3, making daridorexant the first insomnia pharmacotherapy to demonstrate improvement on both nighttime sleep and a validated daytime functioning instrument in a registration program [5]. The improvement reflected reduction in daytime sleepiness, mood disturbance, and functional impairment associated with insomnia. The 25 mg dose showed numerical improvement on the IDSIQ but did not consistently reach statistical significance.

Discontinuation and safety: Adverse events leading to discontinuation occurred in 1 to 3 percent of patients across all treatment groups (including placebo), a rate that did not differ meaningfully between active treatment and placebo.

7.4 Sleep architecture analysis

A pooled post hoc analysis of polysomnographic data from both Phase 3 trials examined the effects of daridorexant on sleep architecture [14]. At month 3, daridorexant 50 mg decreased the probability of wake-to-wake transitions and increased the probability of transitions from wake to N1, N2, and REM sleep, consistent with improved sleep continuity. The compound did not alter EEG spectral power in N2, N3, or REM stages and did not affect sleep spindle frequency, density, or amplitude. Relative beta power during wake and N1 stages decreased (consistent with reduction of hyperarousal), while relative delta power during wake increased. These findings confirm that daridorexant reduces wake-promoting arousal signals without disrupting the intrinsic electrophysiological properties of physiological sleep stages.

7.5 Long-term extension study

A 40-week open-label extension study enrolled patients who completed the Phase 3 pivotal trials and continued treatment with daridorexant 25 mg or 50 mg for a total treatment duration of up to 12 months [7]. The extension study confirmed the durability of the sleep-promoting efficacy through the full treatment period, with no evidence of tolerance (attenuation of effect over time). On abrupt discontinuation after 12 months of treatment, there was no evidence of withdrawal symptoms and no rebound insomnia (sleep parameters returned to baseline values without overshoot). The safety profile in the extension study was consistent with the pivotal trial experience, with no new or unexpected adverse events.

7.6 Special populations in clinical trials

Elderly patients (age 65 years and older) were prospectively included in both Phase 3 pivotal trials and in the long-term extension study. Subgroup analyses confirmed efficacy in the elderly population, with no requirement for dose adjustment based on age. A post hoc analysis of patients with comorbid insomnia disorder and untreated mild obstructive sleep apnea demonstrated that daridorexant did not worsen respiratory parameters and produced sleep improvements comparable to those in patients without obstructive sleep apnea [21].

8. Sourcing and Quality Verification

Pharmaceutical-grade daridorexant (Quviviq, Idorsia Pharmaceuticals Ltd) is the highest quality source for any application. The pharmaceutical material is supplied as 25 mg and 50 mg film-coated tablets containing daridorexant hydrochloride. Pharmaceutical sourcing is available through prescription in jurisdictions where the compound is registered (United States, European Union member states, Switzerland, United Kingdom, Canada, Japan, Australia).

Research-grade daridorexant is supplied by multiple chemical and pharmaceutical research suppliers (MedChemExpress, Selleckchem, Cayman Chemical, BenchChem, MedKoo Biosciences, and others) at greater than 98 percent purity by HPLC. Supply is available in milligram to gram quantities as the free base or as the hydrochloride salt.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (451.16 plus or minus 0.01 for the protonated free base $[M+H]^+$)
- Chiral HPLC confirmation of enantiomeric purity (greater than 99 percent enantiomeric excess of the (S) form)
- Nuclear magnetic resonance spectroscopy (1H and ^{13}C) for structural confirmation
- Karl Fischer or loss-on-drying analysis for residual water content
- Residual solvent analysis by gas chromatography

Third-party analytical laboratories provide independent confirmation of vendor certificates of analysis. The research-grade daridorexant supply is relatively well established given the compound's recent approval; investigators should nonetheless verify lot-to-lot consistency for any study where dose-response precision is important.

9. Reconstitution and Handling

Daridorexant hydrochloride is soluble in dimethyl sulfoxide (DMSO) at concentrations suitable for in vitro research (typically 10 to 50 mM stock solutions). Solubility in aqueous media is moderate; for in vivo research formulations, the compound may be prepared as a suspension in standard oral gavage vehicles (0.5 percent methylcellulose, 0.1 percent Tween 80 in water) or dissolved in acidified aqueous solutions at lower concentrations.

Storage of the solid compound is recommended at room temperature (15 to 25 degrees Celsius) in a dry, light-protected environment. DMSO stock solutions should be aliquoted for single use to avoid freeze-thaw degradation and stored at minus 20 degrees Celsius; stability under these conditions is typically at least 6 months. Aqueous formulations should be prepared fresh or used within 24 hours of preparation unless stability data for the specific vehicle are available.

For clinical-research applications, the pharmaceutical tablet formulation (Quviviq 25 mg or 50 mg film-coated tablets) is the recommended source. The tablets are stable at room temperature and are suitable for direct oral administration in their intact form. Crushing or splitting of the film-coated tablets for dose adjustment is not recommended in the prescribing information but has been used in research settings where intermediate doses are required; investigators using crushed material should verify dose uniformity.

10. Stack Interactions and Combinations

Daridorexant interacts with several drug classes through its CYP3A4-mediated metabolism and through its pharmacodynamic mechanism. Investigators conducting research with daridorexant should consider:

CYP3A4 inhibitors: Strong CYP3A4 inhibitors (itraconazole, clarithromycin, ritonavir, ketoconazole, posaconazole, cobicistat, nefazodone) are contraindicated owing to greater than 400 percent increases in daridorexant AUC. Moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole, verapamil, grapefruit juice) increase AUC by approximately 240 percent; the daridorexant dose should be reduced to 25 mg when these agents are coadministered [16, 17].

CYP3A4 inducers: Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort, efavirenz) substantially reduce daridorexant exposure and are expected to reduce efficacy. Concomitant use with strong inducers is not recommended.

Other CNS depressants: Concomitant use with benzodiazepines, opioids, tricyclic antidepressants, alcohol, or other CNS depressants may produce additive sedative effects. The prescribing information recommends dose adjustment (25 mg) when coadministered with other CNS depressants [16].

Alcohol: Concomitant use with alcohol produces additive psychomotor impairment and is not recommended.

Other DORAs: Concurrent administration with suvorexant or lemborexant is pharmacologically redundant and has not been studied. The combination is not recommended.

SSRI and SNRI antidepressants: A dedicated drug-drug interaction study with citalopram demonstrated no clinically meaningful pharmacokinetic interaction [20]. Daridorexant can be coadministered with SSRIs and SNRIs without dose adjustment. Pharmacodynamic interactions (additive sedation with mirtazapine, trazodone, or other sedating antidepressants) should be considered.

Anticonvulsants: Gabapentin and pregabalin may produce additive sedative effects with daridorexant. No pharmacokinetic interaction is expected, as these agents are renally eliminated and do not interact with CYP3A4.

Melatonin and melatonin receptor agonists: The combination of daridorexant with melatonin, ramelteon, or tasimelteon targets complementary sleep-promoting mechanisms (orexinergic wake suppression plus melatonergic circadian entrainment). The combination has not been formally studied but is plausible for research applications; additive sedation should be anticipated.

P-glycoprotein substrates and inhibitors: Daridorexant is not a clinically significant substrate or inhibitor of P-glycoprotein at therapeutic concentrations. No dose adjustment is required for P-glycoprotein-mediated interactions.

11. Adverse Events and Safety

11.1 Common adverse events

The principal adverse events reported in the Phase 3 pivotal trials at registered doses (25 mg and 50 mg) were [5, 7]:

- Nasopharyngitis (6 to 8 percent in active treatment groups versus 5 to 7 percent in placebo)
- Headache (4 to 6 percent versus 4 to 5 percent in placebo)
- Somnolence (2 to 3 percent versus 1 percent in placebo)
- Fatigue (1 to 3 percent versus 1 percent in placebo)
- Dizziness (1 to 2 percent versus 1 percent in placebo)
- Nausea (1 to 2 percent versus 1 percent in placebo)

Adverse-event rates were generally low and comparable to placebo. The absence of anticholinergic effects (dry mouth, urinary retention, blurred vision), myorelaxant effects (ataxia, falls), or amnestic effects distinguishes daridorexant from the benzodiazepines and Z-drugs.

11.2 Adverse events of special interest

The prescribing information identifies several adverse events of special interest based on the pharmacological class and on the phenotype of narcolepsy (a condition of orexin deficiency) [16]:

Sleep paralysis: An inability to move or speak for up to several minutes during sleep-wake transitions. Reported in 1 patient receiving daridorexant 50 mg and 1 patient receiving daridorexant 25 mg in Study 1, and 2 patients receiving daridorexant 25 mg in Study 2. Overall incidence is low and comparable to the base rate of sleep paralysis in the general population.

Hypnagogic and hypnopompic hallucinations: Vivid perceptual experiences during sleep-wake transitions. Reported at low incidence in the clinical program, consistent with the known pharmacological profile of orexin receptor antagonism.

Cataplexy-like symptoms: Brief episodes of muscle weakness or paralysis. Not reported in the pivotal trials at registered doses; this adverse event is a theoretical concern based on the narcolepsy phenotype.

Complex sleep behaviors: Sleepwalking, sleep-driving, and other activities performed while not fully awake. The prescribing information includes a warning for complex sleep behaviors, consistent with the class labeling for all insomnia pharmacotherapies.

Worsening of depression and suicidal ideation: Suicidal ideation was reported in one patient receiving daridorexant 25 mg and one receiving 10 mg; both had pre-existing psychiatric conditions (paranoid schizophrenia or depression). Both events were assessed as potentially treatment-related. The prescribing information includes a warning regarding worsening of depression and suicidal thinking [16].

Next-morning impairment: Daridorexant may impair alertness and motor coordination the morning after administration. Patients should be cautioned about next-day driving, especially if less than a full night of sleep remains or if the dose is taken later than recommended.

11.3 Long-term safety

The 40-week open-label extension study (total treatment duration up to 12 months) demonstrated no new safety signals, no evidence of tolerance, and no evidence of withdrawal or rebound insomnia upon discontinuation [7]. The adverse-event profile was consistent with the pivotal trial experience. No clinically meaningful changes in vital signs, laboratory parameters, or electrocardiographic intervals were observed during long-term treatment.

11.4 Abuse potential and dependence

Daridorexant is a Schedule IV controlled substance based on human abuse potential data. At the registered 50 mg dose, drug-liking scores were similar to placebo. At supratherapeutic doses (100 mg and 150 mg), dose-dependent drug-liking was observed, broadly similar to zolpidem 30 mg and suvorexant 40 mg. Individuals with a history of substance abuse may be at increased risk. No physical dependence or withdrawal syndrome has been demonstrated at therapeutic doses in the clinical program [7, 11, 19].

11.5 Pregnancy and lactation

Animal reproductive toxicity studies with daridorexant did not demonstrate teratogenicity at exposure multiples exceeding the human therapeutic exposure. However, data in pregnant women are insufficient to establish safety. The compound is present in animal milk; human lactation data are not available. Use in pregnancy and lactation should be considered only when the potential benefit justifies the potential risk.

12. Comparative Assessment

This section presents a structured comparative assessment of five alternative insomnia pharmacotherapies against daridorexant, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected as the principal pharmacological agents used in the treatment of insomnia disorder, with priority on those that have produced material clinical evidence and on those that share daridorexant's clinical positioning as chronic insomnia treatment options.

12.1 Suvorexant (Belsomra)

Mechanism: Dual orexin receptor antagonist (DORA). The first approved DORA, suvorexant binds OX1R and OX2R with K_i values of 0.55 nM and 0.35 nM, respectively. It is a competitive, reversible antagonist with the same fundamental mechanism as daridorexant [22].

Development trajectory: Developed by Merck and Co. Approved by the FDA in August 2014 at doses of 10 mg and 20 mg for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Novelty: High at the time of approval (first-in-class DORA). Low relative to daridorexant, which shares the same mechanism.

Effect size: Phase 3 trials demonstrated statistically significant improvements in WASO and subjective total sleep time (sTST). Effect sizes on polysomnographic endpoints were moderate, broadly comparable to daridorexant 25 mg. A network meta-analysis found that daridorexant 50 mg produced superior improvement in subjective total sleep time compared to suvorexant 20/15 mg [23]. Suvorexant has not demonstrated improvement on a validated daytime functioning instrument.

Promising potential: Moderate. The compound is established in clinical use and has an extensive real-world safety database. Patent expiration is approaching, and generic entry is anticipated.

Side-effect profile: The most common adverse events are somnolence, headache, dizziness, abnormal dreams, dry mouth, and cough. The terminal half-life of 12 hours (compared to 8 hours for daridorexant) contributes to a greater incidence of next-morning residual somnolence. Sleep paralysis and hypnagogic hallucinations are reported at low incidence. Schedule IV controlled substance.

Overall validation: High. The compound has extensive Phase 3, long-term extension, and real-world postmarketing data. It established the clinical proof of concept for the DORA class.

Comparison to daridorexant: Daridorexant has a shorter half-life (8 versus 12 hours), which translates to less next-morning residual sedation at equipotent doses. Daridorexant has demonstrated improvement in daytime functioning (IDSIQ), which suvorexant has not. The network meta-analysis suggests modestly greater efficacy for daridorexant 50 mg on subjective total sleep time. The fundamental mechanism is identical; the differentiation is pharmacokinetic.

12.2 Lemborexant (Dayvigo)

Mechanism: Dual orexin receptor antagonist (DORA). Lemborexant binds OX1R and OX2R with K_i values of 5.4 nM and 0.61 nM, respectively, showing approximately 9-fold selectivity for OX2R over OX1R. This selectivity profile differs from the approximately balanced OX1R/OX2R potency of daridorexant and suvorexant [24].

Development trajectory: Developed by Eisai. Approved by the FDA in December 2019 at doses of 5 mg and 10 mg for the treatment of insomnia.

Novelty: Low within the DORA class. The modest OX2R selectivity is a differentiating feature relative to suvorexant and daridorexant but has not been conclusively shown to produce clinically meaningful differences.

Effect size: Phase 3 trials (SUNRISE 1 and SUNRISE 2) demonstrated statistically significant improvements in LPS and WASO. A network meta-analysis found that lemborexant 10 mg was the most effective treatment for reducing subjective sleep onset latency (sSOL), while daridorexant 50 mg was superior for subjective total sleep time [23]. The clinical significance of these differential effect sizes is modest.

Promising potential: Moderate. The compound is established in clinical use. Eisai continues to invest in label expansion.

Side-effect profile: The most common adverse events are somnolence, headache, and abnormal dreams. The terminal half-life is approximately 17 to 19 hours (substantially longer than daridorexant at 8 hours), which produces greater next-morning residual effects at the 10 mg dose. Somnolence incidence is higher with lemborexant 10 mg than with daridorexant 50 mg in cross-trial comparisons. Schedule IV controlled substance.

Overall validation: High. Extensive Phase 3 and long-term data are available.

Comparison to daridorexant: The principal differentiation is pharmacokinetic. Daridorexant's 8-hour half-life provides a substantially better ratio of nighttime efficacy to next-morning residual impairment than lemborexant's 17- to 19-hour half-life. Lemborexant may have advantages in sleep onset latency reduction; daridorexant has advantages in daytime functioning and in total sleep time.

12.3 Zolpidem (Ambien)

Mechanism: Non-benzodiazepine positive allosteric modulator of the GABA-A receptor, selective for alpha-1-containing GABA-A receptor subtypes. The mechanism produces widespread neuronal inhibition, fundamentally different from the orexin receptor antagonism of daridorexant [25].

Development trajectory: Developed by Synthélabo (now Sanofi). Approved by the FDA in 1992. The most widely prescribed insomnia pharmacotherapy globally for over three decades.

Novelty: Low. The compound and mechanism are well established.

Effect size: Well-demonstrated reduction in sleep onset latency and modest improvement in total sleep time. Effect sizes on WASO are more modest than the DORAs. Suppression of REM sleep and alteration of NREM spectral properties limit the qualitative improvement in sleep. No demonstrated improvement in daytime functioning.

Promising potential: Low for innovation. The compound is in extensive generic competition and is the default comparator for clinical trial design in insomnia.

Side-effect profile: Amnesia, complex sleep behaviors (sleepwalking, sleep-eating, sleep-driving), next-morning impairment, falls (especially in elderly patients), tolerance with chronic use, physical dependence, withdrawal syndrome (including

rebound insomnia), and abuse potential. The FDA added a boxed warning in 2019 for complex sleep behaviors resulting in serious injuries. Schedule IV controlled substance. The side-effect profile is substantially broader and more severe than daridorexant.

Overall validation: Very high. Decades of clinical experience and an enormous postmarketing safety database. However, the safety concerns (tolerance, dependence, complex sleep behaviors, falls) have driven clinical interest in alternatives.

Comparison to daridorexant: Daridorexant produces sleep through a mechanistically distinct pathway, preserves sleep architecture (zolpidem suppresses REM and alters NREM), does not produce tolerance or physical dependence (zolpidem does), carries no risk of amnesia or complex sleep behaviors beyond baseline rates, and has demonstrated improvement in daytime functioning. Zolpidem has faster onset of action for acute sleep onset and decades more clinical experience.

12.4 Eszopiclone (Lunesta)

Mechanism: Non-benzodiazepine positive allosteric modulator of the GABA-A receptor, binding at the benzodiazepine site with broader subtype selectivity than zolpidem [26].

Development trajectory: Developed by Sepracor (now Sunovion). Approved by the FDA in 2004. The first insomnia pharmacotherapy approved without a limitation on duration of use.

Novelty: Low. The mechanism and class are well established.

Effect size: Phase 3 trials demonstrated improvements in sleep onset latency, WASO, and total sleep time at 2 mg and 3 mg doses. Effect sizes on WASO are comparable to the DORAs. Some evidence for improvement in daytime functioning at the 3 mg dose, though the evidence base is less robust than the daridorexant IDSIQ data.

Promising potential: Low for innovation. Available as generic.

Side-effect profile: Unpleasant taste (dysgeusia, reported in approximately 30 percent of patients at the 3 mg dose), headache, somnolence, dizziness, dry mouth. Tolerance is less pronounced than with zolpidem but has been reported. Physical

dependence and withdrawal are possible with chronic use. Complex sleep behaviors are a labeled risk. The dysgeusia is a distinctive tolerability limitation. Schedule IV controlled substance.

Overall validation: High. Extensive Phase 3 and long-term data.

Comparison to daridorexant: Daridorexant lacks the dysgeusia, the GABA-A-mediated side effects (amnesia, tolerance, dependence), and the REM-suppressive sleep architecture effects of eszopiclone. Eszopiclone has longer clinical experience and is available at lower cost as a generic.

12.5 Trazodone (off-label use)

Mechanism: Serotonin antagonist and reuptake inhibitor (SARI). At the low doses used for insomnia (25 to 100 mg), the dominant pharmacological effect is histamine H1 receptor antagonism and alpha-1 adrenergic antagonism, producing sedation. The serotonin reuptake inhibition and 5-HT2A/2C antagonism contribute at higher (antidepressant) doses [27].

Development trajectory: Developed as an antidepressant and approved by the FDA in 1981. Off-label use for insomnia has made it one of the most commonly prescribed sleep-promoting agents in the United States, though it has never been approved for this indication.

Novelty: Low. The compound is generic, off-patent, and widely used off-label.

Effect size: The evidence base for trazodone in insomnia is surprisingly limited given its widespread use. Small randomized controlled trials have demonstrated modest improvements in sleep onset latency and total sleep time. Effect sizes are generally smaller than the DORAs or the Z-drugs on polysomnographic endpoints. No registration-quality insomnia trials have been conducted.

Promising potential: Low for innovation. Established off-label use pattern.

Side-effect profile: Sedation, orthostatic hypotension, dry mouth, blurred vision, priapism (rare but serious; predominantly in males), cardiac arrhythmias (at higher doses), and QT prolongation. The alpha-1 adrenergic antagonism produces orthostatic hypotension that is particularly concerning in elderly patients and contributes to falls risk. No formal tolerance or dependence has been demonstrated at insomnia doses.

Overall validation: Low for the insomnia indication specifically. No registration-quality insomnia trials despite decades of off-label use. Validation as an antidepressant is high.

Comparison to daridorexant: Daridorexant has a substantially stronger evidence base for insomnia (two Phase 3 trials, long-term extension, validated daytime functioning endpoints) and a more favorable side-effect profile (no orthostatic hypotension, no priapism risk, no cardiac conduction effects). Trazodone has the practical advantages of low cost, generic availability, absence of controlled substance scheduling, and simultaneous antidepressant activity in patients with comorbid insomnia and depression.

12.6 Comparator summary

The five comparators occupy distinct positions in the insomnia pharmacotherapy landscape. **Suvorexant** is the class precedent for DORAs, with identical mechanism but a longer half-life that produces more next-morning residual effects. **Lemborexant** is a second DORA with an even longer half-life and modest OX2R selectivity; its pharmacokinetic profile is less optimized for the full-night-coverage-without-morning-impairment goal than daridorexant. **Zolpidem** is the historical standard with the broadest clinical experience but carries the liabilities of GABA-A modulation: tolerance, dependence, amnesia, complex sleep behaviors, and REM suppression. **Eszopiclone** shares the GABA-A mechanism with a distinctive dysgeusia burden. **Trazodone** is the most widely used off-label option, with weak evidence, significant adverse-event liability (orthostatic hypotension, priapism), and no registration-quality insomnia data.

Daridorexant occupies a distinctive position in this landscape as the DORA with the most optimized pharmacokinetic profile for the insomnia indication. The 8-hour half-life is specifically matched to the 8-hour sleep period; the 62 percent oral bioavailability and rapid absorption support reliable onset; and the CYP3A4-dominated metabolism, while producing a drug-interaction liability, is well-characterized and manageable. The compound is the only insomnia pharmacotherapy to have demonstrated improvement on both polysomnographic sleep parameters and a validated daytime functioning instrument in a registration program, a finding that reflects both the mechanism-based preservation of sleep quality and the optimized pharmacokinetics that minimize next-day impairment.

The principal limitations of daridorexant relative to the comparators are: cost (branded prescription, not yet generic), CYP3A4 interaction liability (contraindicating use with strong inhibitors), and the relatively short postmarketing experience compared to zolpidem and trazodone. Investigators considering daridorexant for research applications should consider the comparative advantages in sleep architecture preservation, absence of tolerance and dependence, and the demonstrated daytime functioning benefit when evaluating the compound against the established alternatives.

13. References

1. Treiber A, de Kanter R, Roch C, et al. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. *Psychopharmacology (Berl)*. 2021;238(11):3169-3181.
2. Boss C, Roch C, Treiber A, et al. Discovery and optimization of dual orexin receptor antagonists (DORAs) for the treatment of insomnia. *Chimia (Aarau)*. 2020;74(5):372-378.
3. Boss C, Brotschi C, Gude M, et al. Identification, synthesis, and development of daridorexant: a novel dual orexin receptor antagonist with optimal pharmacokinetic properties. *J Med Chem*. 2020;63(23):15070-15083.
4. World Intellectual Property Organization. Patent WO2014/108785A1. Benzimidazole derivatives as dual orexin receptor antagonists. Filed January 2014.
5. Mignot E, Mayleben D, Fietze I, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. *Lancet Neurol*. 2022;21(2):125-139.
6. Kunz D, Dauvilliers Y, Benes H, et al. Key results from two phase 3 trials on the efficacy and safety of daridorexant in patients with chronic insomnia disorder: a plain language summary. *Future Neurol*. 2023;18(2):FNL55.
7. Kunz D, Benes H, Garcia-Borreguero D, et al. Long-term safety and tolerability of daridorexant in patients with insomnia disorder. *CNS Drugs*. 2023;37(1):93-106.
8. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell*. 1998;92(4):573-585.
9. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. *Cell*. 1999;98(4):437-451.
10. Dauvilliers Y, Zammit G, Leger D, et al. Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder. *Ann Neurol*. 2020;87(3):347-356.

11. United States Drug Enforcement Administration. Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV. Federal Register. 2022;87(67):19987-19991.
12. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. *Neuron*. 2000;27(3):469-474.
13. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. *Nature*. 2005;437(7063):1257-1263.
14. Boof ML, Mang GM, Botta M, et al. Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies. *Sleep*. 2024;47(11):zsae098.
15. Recourt K, de Boer P, van der Ark P, et al. Anxiolytic-like effects of the dual orexin receptor antagonist daridorexant in rats. *J Psychopharmacol*. 2023;37(8):825-833.
16. Idorsia Pharmaceuticals US Inc. Quviviq (daridorexant) prescribing information. US Food and Drug Administration. Approved January 2022.
17. European Medicines Agency. Quviviq (daridorexant) summary of product characteristics. EMA/CHMP. Approved April 2022.
18. Muehlan C, Heuberger J, Juif PE, et al. Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment. *Clin Pharmacokinet*. 2022;61(2):255-266.
19. Fichna J, Myszor S, Gach-Janczak K. Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats. *J Psychopharmacol*. 2024;38(1):72-82.
20. Muehlan C, Brooks S, Zuiker R, et al. Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects. *Eur J Drug Metab Pharmacokinet*. 2021;46(4):547-558.
21. Lettieri C, Fietze I, Engelen J, et al. The effects of daridorexant on patients with comorbid insomnia disorder and untreated mild obstructive sleep apnoea: a post hoc subgroup analysis of a phase 3, randomised clinical trial. *J Sleep Res*. 2026;35(2):e70135.

22. Cox CD, Breslin MJ, Whitman DB, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. *J Med Chem*. 2010;53(14):5320-5332.
23. Liu Y, Wang Y, Chen H, et al. Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. *Transl Psychiatry*. 2025;15:165.
24. Yoshida Y, Naoe Y, Terauchi T, et al. Discovery of (1R,2S)-2-[[2,4-dimethylpyrimidin-5-yl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide (E2006): a potent and efficacious oral orexin receptor antagonist. *J Med Chem*. 2015;58(11):4648-4664.
25. Lancel M. Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. *Sleep*. 1999;22(1):33-42.
26. Najib J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. *Clin Ther*. 2006;28(4):491-516.
27. Jaffer KY, Chang T, Vanle B, et al. Trazodone for insomnia: a systematic review. *Innov Clin Neurosci*. 2017;14(7-8):24-34.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Daridorexant (Quviviq) is approved by the United States Food and Drug Administration and the European Medicines Agency for the treatment of insomnia disorder in adults. It is a Schedule IV controlled substance in the United States. The compound is available by prescription in approved jurisdictions. Investigators should consult their local regulatory authority and institutional review board before any human research application. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly.